Biomarkers of latent TB infection

Expert Review of Respiratory Medicine

Volumn 3, Issue 4, 2009, Pages 387-401

  Ruhwald, Morten ^a   Ravn, Pernille ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; Diagnosis; ESAT 6; IGRA; IP 10; Latent tuberculosis infection; Prevention; TB

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; BCG VACCINATION; DENDRITIC CELL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GRANULOMATOUS INFLAMMATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREDICTIVE VALIDITY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION; TUBERCULIN TEST; TUBERCULOSIS;

EID: 70049108505     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.31     Document Type: Review

References (135)

1. WHO Report. Global tuberculosis control: surveillance, planning financing. WHO/HTM/TB/2005. WHO, Geneva, Switzerland (2005).
2. WHO Report. Global tuberculosis control: surveillance, planning, financing. WHO, Geneva, Switzerland (2008).
3. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44, 714-720 (2005).
4. Frothingham R, Stout JE, Hamilton CD. Current issues in global tuberculosis control. Int. J. Infect. Dis. 9, 297-311 (2005).
5. Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev. Vaccines 7(9), 1341-1356 (2008).
6. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm. Rep. 49, 1-51 (2000).
7. Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. CDC. MMWR Recomm. Rep. 52, 15-18 (2003).
8. Cunningham J, Perkins M; WHO/TDR Tuberculosis Diagnostics Economic Working Group. Diagnostics for Tuberculosis. Global Demand and Market Potential. WHO, Geneva, Switzerland (2008).
9. Atkinson AJ, Colburn WA, DeGruttola VG et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
10. Mack U, Migliori GB, Sester M et al.; TBNET CLft. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 33, 956-973 (2009).
11. Larsen MV, Sorensen IJ, Thomsen VO, Ravn P. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur. Respir. J. 32, 229-231 (2008).
12. Lillebaek T, Bergstedt W, Tingskov PN et al. Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique. Tuberculosis (Edinb.) 89, 158-162 (2009).
13. van der Wel N, Hava D, Houben D et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129, 1287-1298 (2007).
14. Winau F, Weber S, Sad S et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24, 105-117 (2006).
15. Krutzik SR, Modlin RL. The role of Toll-like receptors in combating mycobacteria. Semin. Immunol. 16, 35-41 (2004).
16. Flynn JL, Chan J. Immunology of tuberculosis. Ann. Rev. Immunol. 19, 93-129 (2001).
17. Sharma SK, Mohan A, Sharma A, Mitra DK. Miliary tuberculosis: new insights into an old disease. Lancet Infect. Dis. 5, 415-430 (2005).
18. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol. 26, 677-704 (2008).
19. Kaufmann SHE, Parida SK. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 4, 219-228 (2008).
20. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20-30 (2001).
21. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol. Cell. Biol. 85, 103-111 (2007).
22. Di Liberto D, Locati M, Caccamo N et al. Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J. Exp. Med. 205(9), 2075-2084 (2008).
23. low/- regulatory T cells from peripheral blood lymphocytes of healthy Mycobacterium tuberculosis-infected humans. Microbes Infect. 9, 1325-1332 (2007).
24. Scott-Browne JP, Shafiani S, Tucker-Heard G et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204, 2159-2169 (2007).
25. + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl Acad. Sci. USA 104, 19446-19451 (2007).
26. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008).
27. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48, 171-197 (2008).
28. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 25, 787-820 (2007).
29. Thelen M, Stein J. How chemokines invite leukocytes to dance. Nat. Immunol. 9, 953-959 (2008).
30. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 9, 970-980 (2008).
31. Lande R, Giacomini E, Grassi T et al. IFN-αβ released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells. J. Immunol. 170, 1174-1182 (2003).
32. Qu C, Edwards EW, Tacke F et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J. Exp. Med. 200, 1231-1241 (2004).
33. Chiu BC, Freeman CM, Stolberg VR et al. Cytokine-chemokine networks in experimental mycobacterial and schistosomal pulmonary granuloma formation. Am. J. Respir. Cell Mol. Biol. 29, 106-116 (2003).
34. Jang S, Uzelac A, Salgame P. Distinct chemokine and cytokine gene expression pattern of murine dendritic cells and macrophages in response to Mycobacterium tuberculosis infection. J. Leukoc. Biol. 84, 1264-1270 (2008).
35. Jeyanathan M, Mu J, Kugathasan K et al. Airway delivery of soluble mycobacterial antigens restores protective mucosal immunity by single intramuscular plasmid DNA tuberculosis vaccination: role of proinflammatory signals in the lung. J. Immunol. 181, 5618-5626 (2008).
36. Kaplan G, Luster AD, Hancock G, Cohn ZA. The expression of a γ interferon-induced protein (IP-10) in delayed immune responses in human skin. J. Exp. Med. 166, 1098-1108 (1987).
37. + T cell recruitment during the DTH response to HSV-1 yet are independent of the mechanism for viral clearance. Virology 333, 1-9 (2005).
38. Steingart KR, Henry M, Laal S et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med. 4, e202 (2007).
39. Bagheri K, Delirezh N, Moazzeni SM. PPD extract induces the maturation of human monocyte-derived dendritic cells. Immunopharmacol. Immunotoxicol. 30, 91-104 (2008).
40. Harboe M. Antigens of PPD, old tuberculin, and autoclaved Mycobacterium bovis BCG studied by crossed immunoelectrophoresis. Am. Rev. Respir. Dis. 124, 80-87 (1981).
41. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin. Infect. Dis. 17, 968-975 (1993).
42. Arend SM, Franken WP, Aggerbeck H et al. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis (Edinb.) 88, 249-261 (2008).
43. Davies MA, Connell T, Johannisen C et al. Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. AIDS 23, 961-969 (2009).
44. Ferrara G, Losi M, D'Amico R et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367, 1328-1334 (2006).
45. Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int. J. Tuberc. Lung Dis. 11, 1190-1195 (2007).
46. Karam F, Mbow F, Fletcher H et al. Sensitivity of IFN-γ release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS ONE 3, e1441 (2008).
47. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364, 2196-2203 (2004).
48. Luetkemeyer AF, Charlebois ED, Flores LL et al. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am. J. Respir. Crit. Care Med. 175, 737-742 (2007).
49. Mandalakas AM, Hesseling AC, Chegou NN et al. High level of discordant IGRA results in HIV-infected adults and children. Int. J. Tuberc. Lung Dis. 12, 417-423 (2008).
50. Rangaka MX, Wilkinson KA, Seldon R et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am. J. Respir. Crit. Care Med. 175, 514-520 (2007).
51. Richeldi L, Losi M, D'Amico R et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest doi: 10.1378/chest.08-2575 (Epub ahead of print) (2009).
52. Stephan C, Wolf T, Goetsch U et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 22, 2471-2479 (2008).
53. Talati N, Seybold U, Humphrey B et al. Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect. Dis. 9, 15 (2009).
54. Pai M, Lewinsohn DM. Interferon-γ assays for tuberculosis: is anergy the Achilles' heel? Am. J. Respir. Crit. Care Med. 172, 519-521 (2005).
55. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev. Mol. Diagn. 6, 423-432 (2006).
56. Pai M, O'Brien R. Tuberculosis diagnostics trials: do they lack methodological rigor? Expert Rev. Mol. Diagn. 6(4), 509-514 (2006).
57. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149, 177-184 (2008).
58. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 356, 1099-1104 (2000).
59. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 144(Pt 11), 3195-3203 (1998).
60. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J. Clin. Microbiol. 42, 2379-2387 (2004).
61. Leyten EM, Lin MY, Franken KL et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8, 2052-2060 (2006).
62. Harada N, Higuchi K, Yoshiyama T et al. Comparison of the sensitivity and specificity of two whole blood interferon-γ assays for M. tuberculosis infection. J. Infect. 56, 348-353 (2008).
63. Bakir M, Millington KA, Soysal A et al. Prognostic value of a T-cell-based, interferon-γ biomarker in children with tuberculosis contact. Ann. Intern. Med. 149, 777-786 (2008).
64. Hill PC, Jackson-Sillah DJ, Fox A et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 3, e1379 (2008).
65. Goletti D, Carrara S, Mayanja-Kizza H et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 8, 11 (2008).
66. Aabye MG, Ravn P, PrayGod G et al. The impact of HIV infection and CD4 cell count on the performance of an interferon γ release assay in patients with pulmonary tuberculosis. PLoS ONE 4, e4220 (2009).
67. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-γ test. Respir. Res. 7, 56 (2006).
68. Luetkemeyer AF, Charlebois ED, Flores LL et al. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am. J. Respir. Crit. Care Med. 175, 737-742 (2007).
69. Perkins MD, Small PM. Admitting defeat. Int. J. Tuberc. Lung Dis. 10, 1 (2006).
70. Small PM, Perkins MD. More rigour needed in trials of new diagnostic agents for tuberculosis. Lancet 356, 1048-1049 (2000).
71. Soborg B, Ruhwald M, Hetland M et al. Comparison of screening procedures for M. tuberculosis infection among patients with inflammatory diseases. J. Rheumatol. (In press) (2009).
72. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med. 146, 340-354 (2007).
73. Ponce de LD, Cevedo-Vasquez E, Alvizuri S et al. Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J. Rheumatol. 35, 776-781 (2008).
74. Pai M, Joshi R, Dogra S, Zwerling AA et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int. J. Tuberc. Lung Dis. 13, 84-92 (2009).
75. Harada N, Higuchi K, Sekiya Y, Rothel J, Kitoh T, Mori T. Basic characteristics of a novel diagnostic method (QuantiFERON TB-2G) for latent tuberculosis infection with the use of Mycobacterium tuberculosis-specific antigens, ESAT-6 and CFP-10. Kekkaku 79, 725-735 (2004).
76. Schuck SD, Mueller H, Kunitz F et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS ONE 4, e5590 (2009).
77. Kawamura M. Tuberculosis screening of contacts and HCWs in San Francisco. Presented at: 2nd Global Symposium on IGRAs. Duborvnik, Croatia, 29 May-1 June, 2009.
78. Doherty TM, Demissie A, Olobo J et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40, 704-706 (2002).
79. Hill PC, Jackson-Sillah DJ, Fox A et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 3(1), e1379 (2008).
80. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with i Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 177, 1164-1170 (2008).
81. Aichelburg MC, Rieger A, Breitenecker F et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-1-infected individuals. Clin. Infect. Dis. 48, 954-962 (2009).
82. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol. Med. 13, 175-182 (2007).
83. Higuchi K, Harada N, Fukazawa K, Mori T. Relationship between whole-blood interferon-γ responses and the risk of active tuberculosis. Tuberculosis (Edinb.) 88, 244-248 (2008).
84. Jacobsen M, Mattow J, Repsilber D, Kaufmann SHE. Novel strategies to identify biomarkers in tuberculosis. Biol. Chem. 389, 487-495 (2008).
85. Wallis RS, Doherty TM, Onyebujoh P et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 9, 162-172 (2009).
86. Doherty M, Wallis RS, Zumla A; WHOTropical Disease Research/European Commission joint expert consultation group. Biomarkers for tuberculosis disease status and diagnosis. Curr. Opin. Pulmon. Med. 15(3), 181-187 (2009).
87. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM. Biomarkers for TB treatment response: challenges and future strategies. J. Infect. 57, 103-109 (2008).
88. Pai M, Riley LW, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 4, 761-776 (2004).
89. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev. Mol. Diagn. 6(3), 413-422 (2006).
90. Petrovsky N, Harrison LC. Diurnal rhythmicity of human cytokine production: a dynamic disequilibrium in T helper cell type 1/T helper cell type 2 balance? J. Immunol. 158, 5163-5168 (1997).
91. Arend SM, Thijsen SFT, Leyten EMS et al. Comparison of two interferon-γ assays and tuberculin skin test for tracing tuberculosis contacts. Am. J. Respir. Crit. Care Med. 175, 618-627 (2007).
92. Leyten EMS, Arend SM, Prins C, Cobelens FGJ, Ottenhoff THM, van Dissel JT. Discrepancy between Mycobacterium tuberculosis-specific γ interferon release assays using short and prolonged in vitro incubation. Clin. Vaccine Immunol. 14, 880-885 (2007).
93. Munk ME, Arend SM, Brock I, Ottenhoff THM, Andersen P. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J. Infect. Dis. 183, 175-176 (2001).
94. Ravn P, Demissie A, Eguale T et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179, 637-645 (1999).
95. Aagaard C, Brock I, Olsen A, Ottenhoff THM, Weldingh K, Andersen P. Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J. Infect. Dis. 189, 812-819 (2004).
96. Savolainen L, Pusa L, Kim HJ, Sillanpää H, Seppälä I, Tuuminen T. Pilot study of diagnostic potential of the Mycobacterium tuberculosis recombinant HBHA protein in a vaccinated population in Finland. PLoS ONE 3, e3272 (2008).
97. Feske M, Nudelman RJ, Medina M et al. Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin. Vaccine Immunol. 15, 1616-1622 (2008).
98. Denis M, Wedlock DN, McCarthy AR et al. Enhancement of the sensitivity of the whole-blood γ interferon assay for diagnosis of Mycobacterium bovis infections in cattle. Clin. Vaccine Immunol. 14, 1483-1489 (2007).
99. + T cells from TB patients. Tuberculosis 87, 526-534 (2007).
100. Jennes W, Kestens L, Nixon DF, Shacklett BL. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15 - the Amplispot assay. J. Immunol. Method 270, 99-108 (2002).
101. Calarota SA, Otero M, Hermanstayne K et al. Use of interleukin 15 to enhance interferon-γ production by antigen-specific stimulated lymphocytes from rhesus macaques. J. Immunol. Method. 279, 55-67 (2003).
102. Kuerten S, Schlingmann TR, Rajasalu T, Angelov DN, Lehmann PV, Tary-Lehmann M. Lack of disease specificity limits the usefulness of in vitro costimulation in HIV- and HCV-infected patients. Clin. Dev. Immunol. 2008, 590941 (2008).
103. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39, 723-729 (2009).
104. Ulrichs T, Munk ME, Mollenkopf H et al. Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur. J. Immunol. 28, 3949-3958 (1998).
105. Millington KA, Innes JA, Hackforth S et al. Dynamic relationship between IFN-γ and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J. Immunol. 178, 5217-5226 (2007).
106. Hughes AJ, Hutchinson P, Gooding T, Freezer NJ, Holdsworth SR, Johnson PD. Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin. Exp. Immunol. 142, 132-139 (2005).
107. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, Ravn P. IP-10/CXCL10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes. Infect. 9, 806-812 (2007).
108. Ruhwald M, Petersen J, Kofoed K et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS ONE 3, e2858 (2008).
109. Brice GT, Graber NL, Hoffman SL, Doolan DL. Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-γ production and IFN-γ-secreting cells. J. Immunol. Method. 257, 55-69 (2001).
110. Abramo C, Meijgaarden KE, Garcia D et al. Monokine induced by interferon γ and IFN-γ response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes Infect. 8, 45-51 (2006).
111. Fitzgerald-Bocarsly P, Feng D. The role of type I interferon production by dendritic cells in host defense. Biochimie 89, 843-855 (2007).
112. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses: negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281, 14111-14118 (2006).
113. Petrucci R, Abu AN, Gurgel RQ et al. Interferon γ, interferon-γ-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr. Infect. Dis. J. 27, 1073-1077 (2008).
114. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res. Notes 2, 19 (2009).
115. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNγ? PLoS ONE 3, e3901 (2008).
116. Zhou X-H, Obuchowski NA, McClish DK. Statistical Methods in Diagnostic Medicine. John Wiley & Sons, NY, USA (2002).
117. Ruhwald M, Bodmer T, Maier C et al.; on behalf of TBNET. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of TB. Eur. Respir. J. 32(6), 1428-1430 (2008).
118. Ruhwald M. Improving T-cell assays for the diagnosis of active and latent TB infection using IP-10. Presented at: 2nd Global Symposium on IGRAs. Duborvnik, Croatia, 29 May-1 June, 2009.
119. Lighter J, Rigaud M, Huie M, Peng CH, Pollack H. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int. J. Tuberc. Lung Dis. 13, 731-736 (2009).
120. Demissie A, Leyten EM, Abebe M et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 13, 179-186 (2006).
121. Hougardy JM, Schepers K, Place S et al. Heparin-binding-hemagglutinin-induced IFN-γ release as a diagnostic tool for latent tuberculosis. PLoS ONE 2, e926 (2007).
122. Siawaya JF, Bapela NB, Ronacher K, Beyers N, van Helden P, Walzl G. Differential expression of interleukin-4 (IL-4) and IL-4 δ 2 mRNA, but not transforming growth factor β (TGF-β), TGF-β RII, Foxp3, γ interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin. Vaccine Immunol. 15, 1165-1170 (2008).
123. Wassie L, Demissie A, Aseffa A et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time. PLoS ONE 3, e1522 (2008).
124. Wu B, Huang C, Kato-Maeda M et al. Messenger RNA expression of IL-8, FOXP3, and IL-12b differentiates latent tuberculosis infection from disease. J. Immunol. 178, 3688-3694 (2007).
125. Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir. Res. 7, 77 (2006).
126. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J. Infect. 58, 197-204 (2009).
127. Higuchi K, Harada N, Mori T. Interferon-γ responses after isoniazid chemotherapy for latent tuberculosis. Respirology 13, 468-472 (2008).
128. Herrmann JL, Belloy M, Porcher R et al. Temporal dynamics of interferon γ responses in children evaluated for tuberculosis. PLoS ONE 4, e4130 (2009).
129. Djoba Siawaya JF, Bapela NB, Ronacher K et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J. Infect. 56, 340-347 (2008).
130. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int. J. Infect. Dis. 11, 289-299 (2007).
131. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int. J. Tuberc. Lung Dis. 6, 686-692 (2002).
132. Immanuel C, Swamy R, Kannapiran M et al. Neopterin as a marker for cellmediated immunity in patients with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 1, 175-180 (1997).
133. Tozkoparan E, Deniz O, Cakir E et al. The diagnostic values of serum, pleural fluid and urine neopterin measurements in tuberculous pleurisy. Int. J. Tuberc. Lung Dis. 9, 1040-1045 (2005).
134. Azzurri A, Sow OY, Amedei A et al. IFN-γ-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 7, 1-8 (2005).
135. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin. Exp. Immunol. 156, 69-77 (2009).